New cancer vaccine should be celebrated
Summary
Dr. Zorba Paster discusses breakthrough personalized mRNA cancer therapy for metastatic melanoma, developed by Moderna and Merck. The episode highlights the Keynote 942 study, which showed a 49-59% reduction in death risk when combining the vaccine with Keytruda. Dr. Paster explains how this therapeutic vaccine uses a patient’s own tumor to train the immune system, marking a significant step toward individualized cancer treatment despite ongoing regulatory review.
Topics discussed
Introduction to personalized mRNA cancer therapy for melanoma
Details on Intisaran autogen therapy and its mechanism
Combination with Keytruda and immune system response
Keynote 942 study results showing reduced risk of death
Addressing misinformation and regulatory approval status
Future vision of individualized cancer treatment process
Conclusion on side effects and final remarks
Listen ad-free on Castria